DOP023 Predictors of clinical and endoscopic response with vedolizumab for the treatment of moderately-severely active ulcerative colitis: results from the US VICTORY consortium by Dulai, P., Meserve, J., Hartke, J., Chilukuri, P., Chaudrey, K., Koliani-Pace, J.L., Kochhar, G., Parikh, M.P., Shmidt, E., Hirten, R., Luo, M., Barocas, M., Lasch, K., Sultan, K., Swaminath, A., Bohm, M., Lukin, D., Hudesman, D., Shen, B., Siegel, C.A., Sands, B.E., Colombel, J.-F., Kane, S., Loftus, E.V., Singh, S., Sandborn, W.J., Boland, B.S.

Get full text